Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

bioAffinity Technologies (BIAF) Invested Capital (2022 - 2025)

bioAffinity Technologies (BIAF) has disclosed Invested Capital for 4 consecutive years, with $8.9 million as the latest value for Q3 2025.

  • On a quarterly basis, Invested Capital rose 185.23% to $8.9 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.9 million, a 185.23% increase, with the full-year FY2024 number at $3.4 million, down 43.17% from a year prior.
  • Invested Capital was $8.9 million for Q3 2025 at bioAffinity Technologies, up from -$2.0 million in the prior quarter.
  • In the past five years, Invested Capital ranged from a high of $22.0 million in Q3 2022 to a low of -$16.8 million in Q2 2022.
  • A 4-year average of $3.6 million and a median of $5.3 million in 2024 define the central range for Invested Capital.
  • Biggest YoY gain for Invested Capital was 185.23% in 2025; the steepest drop was 156.87% in 2025.
  • bioAffinity Technologies' Invested Capital stood at $11.3 million in 2022, then crashed by 46.38% to $6.1 million in 2023, then plummeted by 43.17% to $3.4 million in 2024, then skyrocketed by 158.65% to $8.9 million in 2025.
  • Per Business Quant, the three most recent readings for BIAF's Invested Capital are $8.9 million (Q3 2025), -$2.0 million (Q2 2025), and $1.4 million (Q1 2025).